vs

Side-by-side financial comparison of Ibotta, Inc. (IBTA) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Ibotta, Inc. is the larger business by last-quarter revenue ($88.5M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -10.0%). Ibotta, Inc. produced more free cash flow last quarter ($20.3M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 3.7%).

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

IBTA vs PBYI — Head-to-Head

Bigger by revenue
IBTA
IBTA
1.2× larger
IBTA
$88.5M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+37.7% gap
PBYI
27.7%
-10.0%
IBTA
More free cash flow
IBTA
IBTA
$5.9M more FCF
IBTA
$20.3M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
3.7%
IBTA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBTA
IBTA
PBYI
PBYI
Revenue
$88.5M
$75.5M
Net Profit
Gross Margin
78.7%
69.3%
Operating Margin
-1.9%
22.7%
Net Margin
Revenue YoY
-10.0%
27.7%
Net Profit YoY
EPS (diluted)
$-0.03
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBTA
IBTA
PBYI
PBYI
Q4 25
$88.5M
$75.5M
Q3 25
$83.3M
$54.5M
Q2 25
$86.0M
$52.4M
Q1 25
$84.6M
$46.0M
Q4 24
$98.4M
$59.1M
Q3 24
$98.6M
$80.5M
Q2 24
$87.9M
$47.1M
Q1 24
$82.3M
$43.8M
Net Profit
IBTA
IBTA
PBYI
PBYI
Q4 25
Q3 25
$1.5M
$8.8M
Q2 25
$2.5M
$5.9M
Q1 25
$555.0K
$3.0M
Q4 24
Q3 24
$17.2M
$20.3M
Q2 24
$-34.0M
$-4.5M
Q1 24
$9.3M
$-4.8M
Gross Margin
IBTA
IBTA
PBYI
PBYI
Q4 25
78.7%
69.3%
Q3 25
79.4%
77.7%
Q2 25
79.2%
76.5%
Q1 25
79.8%
77.1%
Q4 24
84.6%
76.4%
Q3 24
87.7%
63.9%
Q2 24
86.0%
77.4%
Q1 24
87.2%
75.5%
Operating Margin
IBTA
IBTA
PBYI
PBYI
Q4 25
-1.9%
22.7%
Q3 25
2.8%
17.6%
Q2 25
1.4%
12.7%
Q1 25
-3.3%
8.7%
Q4 24
13.2%
22.6%
Q3 24
21.0%
27.4%
Q2 24
-24.6%
-4.6%
Q1 24
19.3%
-5.3%
Net Margin
IBTA
IBTA
PBYI
PBYI
Q4 25
Q3 25
1.8%
16.2%
Q2 25
2.9%
11.2%
Q1 25
0.7%
6.5%
Q4 24
Q3 24
17.5%
25.2%
Q2 24
-38.6%
-9.6%
Q1 24
11.3%
-11.0%
EPS (diluted)
IBTA
IBTA
PBYI
PBYI
Q4 25
$-0.03
$0.26
Q3 25
$0.05
$0.17
Q2 25
$0.08
$0.12
Q1 25
$0.02
$0.06
Q4 24
$3.04
$0.40
Q3 24
$0.51
$0.41
Q2 24
$-1.32
$-0.09
Q1 24
$0.33
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBTA
IBTA
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$186.6M
$97.5M
Total DebtLower is stronger
$0
$22.7M
Stockholders' EquityBook value
$287.7M
$130.3M
Total Assets
$525.9M
$216.3M
Debt / EquityLower = less leverage
0.00×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBTA
IBTA
PBYI
PBYI
Q4 25
$186.6M
$97.5M
Q3 25
$223.3M
$94.4M
Q2 25
$250.5M
$96.0M
Q1 25
$297.1M
$93.2M
Q4 24
$349.3M
$101.0M
Q3 24
$341.3M
$96.7M
Q2 24
$317.9M
$96.8M
Q1 24
$79.5M
$107.2M
Total Debt
IBTA
IBTA
PBYI
PBYI
Q4 25
$0
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$0
$68.0M
Q3 24
$0
$79.3M
Q2 24
$0
$90.7M
Q1 24
$65.3M
$102.0M
Stockholders' Equity
IBTA
IBTA
PBYI
PBYI
Q4 25
$287.7M
$130.3M
Q3 25
$329.6M
$115.3M
Q2 25
$354.1M
$104.7M
Q1 25
$401.3M
$97.1M
Q4 24
$457.3M
$92.1M
Q3 24
$378.0M
$71.1M
Q2 24
$359.7M
$48.5M
Q1 24
$44.1M
$51.0M
Total Assets
IBTA
IBTA
PBYI
PBYI
Q4 25
$525.9M
$216.3M
Q3 25
$569.4M
$202.9M
Q2 25
$600.8M
$194.9M
Q1 25
$639.3M
$196.2M
Q4 24
$678.4M
$213.3M
Q3 24
$598.3M
$220.7M
Q2 24
$556.0M
$205.0M
Q1 24
$322.1M
$214.1M
Debt / Equity
IBTA
IBTA
PBYI
PBYI
Q4 25
0.00×
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.00×
0.74×
Q3 24
0.00×
1.12×
Q2 24
0.00×
1.87×
Q1 24
1.48×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBTA
IBTA
PBYI
PBYI
Operating Cash FlowLast quarter
$27.8M
$14.4M
Free Cash FlowOCF − Capex
$20.3M
$14.4M
FCF MarginFCF / Revenue
22.9%
19.1%
Capex IntensityCapex / Revenue
8.5%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$75.0M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBTA
IBTA
PBYI
PBYI
Q4 25
$27.8M
$14.4M
Q3 25
$21.8M
$9.7M
Q2 25
$25.9M
$14.1M
Q1 25
$19.9M
$3.6M
Q4 24
$22.0M
$15.6M
Q3 24
$39.5M
$11.0M
Q2 24
$35.0M
$1.0M
Q1 24
$19.4M
$11.2M
Free Cash Flow
IBTA
IBTA
PBYI
PBYI
Q4 25
$20.3M
$14.4M
Q3 25
$14.5M
$9.7M
Q2 25
$22.2M
$14.1M
Q1 25
$18.0M
$3.6M
Q4 24
$21.8M
$15.6M
Q3 24
$39.2M
$11.0M
Q2 24
$34.8M
$1.0M
Q1 24
$19.2M
FCF Margin
IBTA
IBTA
PBYI
PBYI
Q4 25
22.9%
19.1%
Q3 25
17.4%
17.7%
Q2 25
25.8%
26.8%
Q1 25
21.2%
7.7%
Q4 24
22.1%
26.4%
Q3 24
39.8%
13.7%
Q2 24
39.6%
2.1%
Q1 24
23.3%
Capex Intensity
IBTA
IBTA
PBYI
PBYI
Q4 25
8.5%
0.0%
Q3 25
8.7%
0.0%
Q2 25
4.2%
0.0%
Q1 25
2.2%
0.1%
Q4 24
0.2%
0.0%
Q3 24
0.3%
0.0%
Q2 24
0.2%
0.0%
Q1 24
0.2%
0.0%
Cash Conversion
IBTA
IBTA
PBYI
PBYI
Q4 25
Q3 25
14.19×
1.10×
Q2 25
10.38×
2.41×
Q1 25
35.78×
1.21×
Q4 24
Q3 24
2.29×
0.54×
Q2 24
Q1 24
2.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBTA
IBTA

Redemption Revenue$78.5M89%
Ad Other Revenue$10.0M11%
Breakage$2.1M2%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons